All In MedTech

Device Trial Radar · NCT07806409

Safety and Clinical Performance of the Next-Generation SAFESYNC Transcatheter Heart Valve in Patients With Severe Aortic Stenosis

Evaluation of the Safety and Clinical Performance of the Next-Generation SAFESYNC Balloon-Expandable Transcatheter Heart Valve in Patients With Severe Aortic Stenosis: A Prospective, Multicenter, Single-Arm Pivotal Study

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingTitle says "pivotal". This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

210

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Jul 2027

Study completion Jun 2032

Sponsor

Lead sponsor
Braile Biomedica Ind. Com. e Repr. Ltda.Not on our public-company list
Sponsor type
Industry
First posted
Sep 8, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This pivotal, prospective, multicenter (Brazil, Chile and Argentina), single-arm study will evaluate the safety and clinical performance of the Inovare® Safesync Next-Generation bioprosthetic heart valve, implanted by transfemoral transcatheter aortic valve implantation (TAVI) with the B-Delivery System, in patients aged 70 years or older with severe aortic stenosis and an indication for TAVI, regardless of surgical risk. The study will enroll 210 participants.

Conditions

  • Aortic Stenosis
  • Aortic Valve Stenosis
  • Severe Aortic Stenosis

Interventions

  • INOVARE® SAFESYNC Next-Generation Bioprosthetic Heart ValveDevice

    Participants will undergo TAVI via transfemoral access using the INOVARE® SAFESYNC Next-Generation Bioprosthetic Heart Valve and the B-Delivery System.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Device Success According to VARC-3 CriteriaTime frame: 30 days after the procedure

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.